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View OnlineLabel-free methods for probing the interaction of clioquinol with amyloid-b†
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DOI: 10.1039/c2ay25123jThe presence of amyloid-b (Ab) fibrils is characteristic of Alzheimer’s disease (AD), and the
aggregation of these amyloidogenic proteins is a nucleation-dependent process. In this report, label-free
methods based on surface plasmon resonance (SPR) and thickness shear mode acoustic wave sensors
(TSM-AWS) were used to detect monomer elongation in real-time. The modulation of Ab aggregation
using a well-described flavonoid, clioquinol (CQ) was also observed. Established methods like
fluorescence and electrochemistry were also employed to confirm the interaction of CQ with Ab. Good
correlation between the designed label-free methods creates a promising platform for the screening of
novel amyloid inhibitors.Introduction
Alzheimer’s disease (AD) is a neurodegenerative disease marked
by clinical symptoms such as a decline in cognitive ability,
alterations in behaviour, irreversible memory loss, and language
impairment.1 The onset of the disease is not considered a natural
pathway of aging2 and is the most prevalent cause of dementia
with about 18 to 30 million patients worldwide.3AD is one of the
most common neurodegenerative diseases including Parkinson’s,
Huntington’s, and Creutzfeld Jacob disease, in which symptom
progression is correlated to the development of neural fibrillary
tangles and neuritic plaques deposited within the limbic and
association cortices of the brain.4,5 One of the major neuro-
pathological hallmarks of AD is the deposition of amyloid-
b (Ab) on the walls of cerebral and meningeal blood vessels as
senile plaques. Amyloid is the generic term describing abnor-
mally fibrillated proteins possessing a b-pleated sheet confor-
mation. In AD, the central core of senile plagues comprise
insoluble amass of fibrillated aggregates of Ab. The cytotoxic
effect of these conformers had been correlated to the onset and
progression of permanent cognitive impairments to memory,
learning, and language.6Ab1-42 in AD patients are formed when
amyloid precursor protein gets cleaved by b- and g-secretases to
produce Ab1-40 and Ab1-42.7Recently, it has been reported that
the oligomeric forms of Ab are neurotoxic.8 There is also accu-
mulating evidence that monomeric form of Ab seems to mediate
the growth of AD amyloid plaques in human brain rather thanaDepartment of Physical and Environmental Sciences, University of
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2228 | Anal. Methods, 2012, 4, 2228–2232mature fibrils.9 Therefore, the study of monomer elongation
might provide clues to therapeutic interventions.
Aggregation of Ab is a nucleation-dependent process.10
Nucleation is followed by the accelerated aggregate growth and
incorporation of soluble aggregates (intermediate species) before
forming mature fibrillar networks. Several advanced analytical
techniques such as circular dichroism spectroscopy, high-resolu-
tion atomic force microscopy and nuclear magnetic resonance
have been applied to study the mechanisms of amyloid forma-
tion.11 However, most of these techniques require complex
instrumentation and tedious sample preparation steps. As such,
robust and rapid analyticalmethods are greatly desired to develop
multiplexed platforms for AD drug screening nowadays, consid-
ering the recent aging population crisis in developed countries.
Recently, reports have been published about the applications
of surface plasmon resonance (SPR) and piezoelectric sensors to
monitor Ab aggregation.12–22 Buell and co-workers12 studied the
interactions between organic dyes and Ab on a thickness shear
mode acoustic wave sensor (TSM-AWS). They proposed that
TSM-AWS could elucidate the interaction of potential inhibitors
with Ab.12Yamada and co-workers15–18 used SPR to characterize
the effect of Ab concentration on aggregation, and calculated the
critical monomer concentration as 20 nM and equilibrium
binding constant of monomers to fibrils as 5  107 M1. Alka-
loids have been tested using SPR to observe their effects on Ab
aggregation.15–18 TSM-AWS studies have proposed a ‘‘dock and
lock’’ mechanism to describe rapid binding of monomers to fibril
aggregates occurring rapidly in a reversible fashion, which was
then followed by a conformational change in structure that
stabilized the aggregates.22 The stabilization process generated
new binding sites to allow further docking of new monomers to
the aggregates.22
Clioquinol (CQ, 5-chloro-7-iodo-8-hydroxyquinoline) was














































View Onlinecognitive behaviour in humans.23,24 It was shown that oral
administration of CQ significantly hindered Ab accumulation in
the brain of Tg2576 mice, and in clinical studies, patients
exhibited slower cognitive decline after CQ treatment.23,24
In this study, label-free biosensing methods were developed
to evaluate the Ab1-42 aggregation in real-time, starting from
seeds immobilized on the sensing surface to act as initiators.
This system was also used to test the inhibitory activity of CQ
on Ab1-42 aggregation. The results of the label-free methods
were supported using the electrochemical and fluorescence data.Experimental
Materials and instruments
Amyloid-b (Ab) peptide Ab1-42 trifluoroacetic salt was
purchased from EMD Chemicals Inc. (Gibbstown, NJ) (peptide
sequence: DAEFRHDSGYEVHHQKLVFFAEDVGSNK-
GAIIG LMVGGVVIA). Thioflavin T (ThT, 4-(3,6-dimethyl-
1,3-benzothiazol-3-ium-2-yl)-N,N-dimethylaniline chloride),
multi-walled carbon nanotubes (MWCNT, 110–170 nm in
diameter, 5–9 mm in length, 90+% purity), graphite powder
(<20 mm, synthetic), mineral oil, ammonium iron(II)sulfate
hexahydrate, ethanolamine HCl (EA), clioquinol (CQ), zinc(II)
chloride, 11-mercapto-1-undecanoic acid (MUA), 1-ethyl-3-(3-
dimethyl-aminopropyl) carbodiimide (EDC) and copper(II)
chloride were purchased from Sigma Aldrich (Oakville, ON). N-
Hydroxysuccinimide (NHS) was purchased from Fluka (Milan,
Italy). All solutions were prepared using double-distilled MilliQ
water, unless otherwise stated. Ammonia (28%) was purchased
from VWR. Hydrogen peroxide (35%) was obtained fromMerck
(Germany). Ethanol and all the reagents for the buffers were
purchased from Merck (Italy).
For SPR measurements, the running buffer contained 5 mM
N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid (HEPES,
pH 7.4), 5 mM HEPES–Na with 150 mM NaCl, 3 mM EDTA
and 0.005% surfactant P20. The buffer was filtered and degassed
before use. EDTA was purchased from Merck (Milan, Italy).
Immobilization buffer contained 10 mM acetic acid and 10 mM
sodium acetate (trihydrate) before adjusting pH using NaOH to
pH 5. Phosphate Buffer Saline (PBS, 50 mM, pH 7.4) with
100 mM NaCl was also used. All other chemicals were of
analytical grade and used without further purification.
Quartz crystals (9.5 MHz AT-Cut, 14 mm) with gold evapo-
rated (42.6 mm2 area) onto both sides were purchased from
International Crystal Manufacturing (Oklahoma, USA). The
measurements were conducted in methacrylate cells, where only
one side of the crystal was in contact with the solution. The
quartz crystal analyzer used for the measurements was theModel
QCA922 (Seiko EG&G, Chiba, Japan) for TSM-AWS studies.
The frequency shifts were calculated from the difference between
two stable frequency signals (1 Hz).
For SPR measurements, the Biacore X (Biacore AB
Uppsala, Sweden) was used with the research grade Au chip (SIA
kit Au). Thermomixer Comfort (Eppendorf, Hamburg, Ger-
many) was used for the incubation of fibrils. The change in
resonance units (RU) was recorded in real time on a sensorgram
where 1 RU was equivalent to one picogram per square milli-
meter on the sensor surface.This journal is ª The Royal Society of Chemistry 2012Label-free methods: TSM-AWS and SPR
Ab1-42 peptides were dissolved in DMSO and stored at 20 C.
The monomers were obtained from the stock solution by soni-
cating the peptides for 5 min before storing at 20 C until use.
The peptides were also diluted to 40 mM using PBS, and then
subjected to 24 h incubation at 37 C with shaking at 800 rpm in
order to produce the fibril seeds.
All fibril seeds and monomers were sonicated for at least 5 min
before use in attempts to obtain the seed solution. Cleaning of the
quartz crystal was performed by boiling for 10 min in a 5 : 1 : 1
(v/v) mixture of water : ammonia : hydrogen peroxide, respec-
tively. The crystal was then incubated in 95% ethanol for 1 h
before immersing in 1 mM MUA overnight to allow film
formation. The immobilization chemistry involved the covalent
peptide bond forming process. The activation of the carboxylic
groups was achieved by reacting the MUA-modified surface with
an aqueous solution of 5.8 mg mL1 NHS and 38.3 mg mL1
EDC for 15 min. The fibril seeds were diluted in PBS to 15 mM,
and sonicated. An aliquot (100 mL) of fibril seeds was introduced
to the activated MUA surface for 30 min. The fibril seed-
immobilized surface was then rinsed with PBS to remove non-
specifically bound species before adding 1 M EA for 15 min to
block any remaining active esters on the surface. An aliquot
(100 mL) of 2 mM Ab1-42 peptide monomers in the absence and
presence of 10 mMCQwas then exposed to the seed-immobilized
surface for 50 min before a subsequent PBS wash. The change in
frequency signals before and after monomer incubation was
recorded.
For SPR measurements, the surface cleaning and modification
procedures were adapted from the detailed study of Mariotti
et al.25 For the EDC/NHS activation of the MUA-modified
surface, the solution was flown at 5 mL min1 for 7 min followed
by the addition of fibril seeds for 30 min at a flow rate of 3 mL
min1. In order to quench the active esters, EA was also added
for 10 min at 5 mL min1. The monomer and CQ were injected at
a flow rate of 2 mL min1 for 50 min. The flow rates were adapted
from the detailed study of Mariotti et al.25 The change in RU
before and after monomer incubation was recorded.Sample preparation for electrochemistry and fluorescence
Solutions were prepared in PBS with 100 mMNaCl and stored at
4 C until use. ThT stock solutions (10 mM) were prepared fresh
with ultrapure water, and stored at room temperature while
shielded from light to prevent photodegradation. A working
solution of 250 mL was prepared containing 50 mM of Ab1-42 in
the presence and absence of 50 mM CQ incubated at 37 C with
shaking to induce the aggregation of Ab1-42.Preparation of multi-walled carbon nanotube-modified carbon
paste electrode (CNT-CPE)
Composition of the CNT-CPE consisted of 10% MWCNT, 60%
graphite powder and 30% mineral oil by weight. Constituents
were mixed thoroughly until a thick paste was created. The paste
was then packed into a carbon paste working electrode body with
3.0 mm internal diameter. Surface of the CNT-CPEs were














































View OnlineSquare wave voltammetry (SWV)
The working electrode was pre-treated each time before
a measurement for 60 s at 1.7 V in PBS, then rinsed with ultra-
pure water. An aliquot (15 mL) of sample was placed on an
inverted CNT-CPE and allowed to adsorb for a duration of 15
min at room temperature. A final rinsing step was done for 5 s
using 10 mL of PBS. Measurements were taken in 10 mL of
solution of PBS using SWVwith a potential range from 0 to 1.3 V
at a frequency of 230 Hz.Fig. 2 Frequency (Hz) vs. time (min) plot showing the decrease in net
frequency change (DF) after a 50 min incubation of 2 mM Ab1-42
monomers on the seed-immobilized surface.Fluorescence spectroscopy
Ab1-42 and CQ samples were prepared in 50 mM PBS with
100 mM NaCl at pH 7.4. ThT fluorescence was collected at
440 nm excitation and 485 nm emission. All samples were incu-
bated at 37 C with shaking. The experimental results were
analyzed using Gen5 Microplate Data Collection and Analysis
Software.Results and discussion
For an effective monitoring of Ab1-42 elongation, it was crucial
to avoid non-specific adsorption of Ab1-42 monomers on the
biosensor surface. With this objective in mind, MUA film was
first formed on the quartz crystal surface and then activated with
EDC/NHS chemistry. The surface was directly saturated with
EA in the absence of seeds, to obtain a ‘control’. On the EA-
passivated surface, a 2 mM monomer solution of Ab1-42 and
subsequently, a 10 mM CQ solution were tested, both showing
negligible signals (Fig. S1A and B†). This result showed that the
non-specific adsorption of the monomers and CQ on the surface
could be suppressed by applying EA.
Ab1-42 sample was incubated for 24 h at 37 C to formmature
fibrils (Fig. S2A†). The fibrils were then sonicated to disintegrate
into small fragments (coinedhere as ‘seeds’) (Fig. S2B†). The seeds
were then immobilized on the covalently activated surface. The
surface was then blocked with EA, so that the unreacted estersFig. 1 Fibril elongation process on the surface of the seed-immobilized
TSM-AWS; (a) baseline signal in buffer, before Ab1-42 monomer addi-
tion on the seed-immobilized surface; (b) deposition and elongation of
Ab1-42 fibrils; (c) surface wash to remove the non-specifically bound
monomers. The analytical signal was calculated as the difference (c–a) in
frequency (Hz).
2230 | Anal. Methods, 2012, 4, 2228–2232would not create further binding sites during the addition of
monomers (Fig. 1). The serial introduction of 2 mM Ab1-42
monomers on the seed-immobilized surface for 50 min induced
a decrease in the measured frequency of 46 7Hz (Table S1† and
Fig. 2). The net decrease in frequency is correlated to the mass
increase on the TSM-AWS. This result supported the previous
hypothesis that fibril formation initiated from nuclei sites.27–37
Bini et al.38 estimated that themass deposited for a change of 1Hz
would correspond to 20 pgmm2. Fromour data, themass change
was about 15 Hz, and thus corresponded to 300 pg mm2 of seeds
immobilized on the surface.When 10 mMCQwas simultaneously
introduced with 2 mM monomer solution for 50 min, the net
decrease in frequency became 6.0 Hz, which was significantly
smaller than the monomer incubation on its own. During the
serial injections, the presence of CQwithmonomers induced a net
increase in frequency (Fig. 3). This implied that the freshly elon-
gated immobilized seeds were lifting off from the sensor surface.
In order to show that the small change in frequencywas not due to
the saturation of the seed-immobilized surface, an incubation of
2 mMmonomer solution alone was performedwith the surface for
50min, and the net decrease in frequencywas 41Hz. This recovery
of the drop in frequency indicated that CQ inhibited the elonga-
tion by interacting more with monomers, but less with the fibril
seeds on the surface.
CQ alone was also introduced to a seed-immobilized surface,
but the net change in frequency (Fig. S3†) was negligibleFig. 3 Serial injections of 2 mM Ab1-42 monomers with 10 mM CQ.
Subsequent injections of 2 mMAb1-42 monomers initiated the elongation
process.
This journal is ª The Royal Society of Chemistry 2012
Fig. 5 The dependence of Tyr-10 oxidation signal of Ab1-42 on time in
the absence (dotted line) and presence of 50 mM CQ (dashed line). Error














































View Onlineindicating that CQ had a weak affinity to the immobilized seeds
on the surface. This was attributed to the hydrophilicity of the
halogen and hydroxyl groups on CQ that prevented the inter-
action of CQ with the hydrophobic core of the fibrils. The results
of these control measurements are listed in Table S1†.
For SPR measurements, the immobilization chemistry and
elongation procedures were similar to that described for the
TSM-AWS-based method. SPR sensorgrams showed different
characteristics of binding to the surface in both cases (Fig. S4A
and B†). Preliminary assays were carried out to verify the
suppression of non-specific adsorption. When Ab1-42 monomers
in the presence and absence of CQ were introduced to the
passivated gold surface, RU signals of about 162 22 and 276 
20 were observed, respectively (Fig. S5†). The monomers in the
presence of CQ resulted in a consistently smaller RU increase
than in its absence. When 2 mM Ab1-42 monomers were intro-
duced to the seed-immobilized surface, a significant response of
541  61 RU was observed, which indicated the attachment of
monomers on the seed-immobilized surface. CQ was also intro-
duced to the EA-passivated surface to test for its non-specific
adsorption on the surface, but only a negligible signal was
observed (data not shown).
To ensure that the Ab1-42 was ‘growing’ on the sensor surface,
four subsequent control experiments were also performed
(Fig. S6†). The results obtained showed stepwise increase in RU
after each injection of the monomers. An increase of approxi-
mately 2000 RU was observed after all the injections, which
corresponded to 32 ng of Ab1-42 being deposited on the surface
with a channel of 16 mm2 area (1000 RU ¼ 1 ng mm2).39
To increase the SPR signal for fibril elongation, the concen-
tration of seeds was doubled to 30 mM. According to Cannon
and co-workers,26 the increase in seed concentration would result
in an increase in the elongation rate. Our results were in
consensus with those previously reported values, as the RU
increase was almost doubled in a time span of 50 min.
Injection of monomers in the presence of 10 mMCQ, caused an
almost 5-fold decrease in RU. CQ alone was also introduced to
the seed-immobilized surface, and did not cause a significant
change in the signal (Fig. 4).
To confirm the results obtained from the label-free studies of
Ab1-42 aggregation in vitro, electrochemical and fluorescence
measurements were performed. Electrochemical monitoring of
Ab aggregation was performed using the well-established
oxidation peak of a lone tyrosine residue (Tyr-10) intrinsic toFig. 4 Sensorgram showing the inhibitory effect of 10 mM CQ on
aggregation, when introduced in the presence and absence of 2 mMAb1-
42 on the seed-immobilized surface.
This journal is ª The Royal Society of Chemistry 2012human Ab1-42.40,41 The magnitude of the oxidation signal at
approximately 0.7 V (vs.Ag/AgCl) was recorded over a 24 h time
span. As Ab1-42 peptides aggregated, and formed large, ordered,
fibrillar species, Tyr-10 became more shielded within the peptide,
therefore less available to be oxidized at the electrode surface.
This caused the observed oxidation signal to decrease as the
aggregation continued.
It was expected that in the absence of aggregation modulators,
Ab1-42 alone would show the most rapid decrease in Tyr-10
oxidation signal, while after the addition of CQ, the time
required to reach the same extent of aggregation would increase.
As shown in Fig. 5, electrochemical assessment of Ab1-42
aggregation kinetics supported this hypothesis, as the decrease
was most significant for the incubation with Ab1-42 alone, and
plateaued shortly after 200 min passed. A similar phenomenon
has been reported recently,42 when baicalein was incubated with
a-synuclein, another amyloidogenic protein, and thus, confirmed
the validity of our electrochemical analysis.
In the presence of CQ, the decrease in the oxidation signal of
Tyr-10 progressed slowly. This indicated that the aggregation of
Ab1-42 was modulated by the flavonoid. As well, the overall
current intensity recorded for Ab1-42 in the presence of CQ wasFig. 6 The dependence of ThT fluorescence signal on time with 50 mM
Ab1-42 in the absence (dotted line) and presence (dashed line) of 50 mM
CQ. Solid line demonstrates that 50 mM CQ alone did not show signifi-
cant fluorescence activity. Error bars represent the standard deviation of
triplicate measurements (n ¼ 3).














































View Onlinehigher than that of Ab1-42 alone, suggesting that the aggregates
formed in the presence of CQ were less densely packed, and as
such allowed for more Tyr-10 residues to be oxidized.
A similar trend was observed in our fluorescence analysis as
depicted in Fig. 6. The use of ThT as a fluorescent dye to monitor
b-sheet formation during peptide aggregation was described
extensively in the past, and as such, provided a reliable method to
validate the results obtained from our label-free experiments. In
the absence of CQ, Ab1-42 alone showed the most significant
increase in fluorescence intensity, as well as the highest values of
relative fluorescence unit (RFU), as expected. Fluorescence of
CQ alone was also monitored to make sure that there were no
significant RFU contributions that could complicate the values
recorded for Ab1-42 in the presence of CQ.
Upon addition of CQ, the first notable difference was the
slower rate of increase in fluorescence. The final intensity of ThT
fluorescence in the presence of CQ was also less intense as
compared to that in its absence. These results corresponded to
what had been observed in the previously described label-free
methods in this report, further supporting the ability of CQ to
modulate the progression of Ab1-42 aggregation.Conclusions
The modulation effects of CQ were observed on the aggregation
of Ab1-42 peptides using piezoelectric and SPR-based methods.
The design of these label-free methods shows good promise in
rapid and cost-effective screening for aggregation modulators,
which would be highly valuable in developing new therapeutic
agents against AD. High-throughput, multiplexed label-free
analysis of novel aggregation modulators is under investigation
in our laboratory.Acknowledgements
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